公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2022 | Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5 | CHEN-HUA LIU ; JIA-HORNG KAO | Hepatology International | 7 | 8 | |
2022 | Paradigm shift in the treatment options of hepatocellular carcinoma | TUNG-HUNG SU ; SHIH-JER HSU ; JIA-HORNG KAO | Liver international : official journal of the International Association for the Study of the Liver | 22 | 18 | |
2002 | Paratyphoid hepatitis: An emerging clinical entity [5] | PO-REN HSUEH ; JIA-HORNG KAO ; YEE-CHUN CHEN ; PAN-CHYR YANG ; KWEN-TAY LUH ; Wang T.-K.; Lin S.-F. | American Journal of Medicine | 7 | 5 | |
2019 | Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis | CHEN-HUA LIU ; Shih Y.-L; Yang S.-S; Lin C.-L; YU-JEN FANG ; Cheng P.-N; Chen C.-Y; Peng C.-Y; Hsieh T.-Y; Chiu Y.-C; TUNG-HUNG SU ; CHUN-JEN LIU ; HUNG-CHIH YANG ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 7 | 7 | |
2020 | Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan | Su H.-J.; JIA-HORNG KAO ; TAI-CHUNG TSENG ; HUNG-CHIH YANG ; TUNG-HUNG SU ; PEI-JER CHEN ; CHUN-JEN LIU | Journal of the Formosan Medical Association | 17 | 12 | |
2019 | Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: A systematic review and meta-analysis of individual participant data | Pavlovic V.; Yang L.; Chan H.L.-Y.; Hou J.; Janssen H.L.; JIA-HORNG KAO ; Lampertico P.; Peng C.-Y.; Piratvisuth T.; Thompson A.J.; Wedemeyer H.; Wei L.; Wat C. | Antiviral Therapy | 10 | 7 | |
2007 | Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV [6] | CHEN-HUA LIU ; DING-SHINN CHEN ; JIA-HORNG KAO | New England Journal of Medicine | 1 | 1 | |
2009 | Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses | CHUN-JEN LIU ; Chuang W.; Lee C.; Yu M.; Lu S.; Wu S.; Liao L.; CHI-LING CHEN ; Kuo H.; Chao Y.; Tung S.; Yang S.; JIA-HORNG KAO ; CHEN-HUA LIU ; Su W.; Lin C.; YUNG-MING JENG ; PEI-JER CHEN ; DING-SHINN CHEN | Gastroenterology | 182 | 157 | |
2015 | Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial | CHEN-HUA LIU ; Huang, Chung-Feng; CHUN-JEN LIU ; Dai, Chia-Yen; Huang, Jee-Fu; JOU-WEI LIN ; Liang, Cheng-Chao; Yang, Sheng-Shun; CHIH-HUNG LIN ; TUNG-HUNG SU ; HUNG-CHIH YANG ; PEI-JER CHEN ; DING-SHINN CHEN ; Chuang, Wan-Long; JIA-HORNG KAO ; Yu, Ming-Lung | Scientific reports | 8 | 8 | |
2015 | Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial | CHEN-HUA LIU ; CHUN-JEN LIU ; Huang C.-F; JOU-WEI LIN ; Dai C.-Y; Liang C.-C; Huang J.-F; Hung P.-H; Tsai H.-B; MENG-KUN TSAI ; CHIH-YUAN LEE ; Chen S.-I; Yang S.-S; TUNG-HUNG SU ; HUNG-CHIH YANG ; PEI-JER CHEN ; DING-SHINN CHEN ; Chuang W.-L; Yu M.-L; JIA-HORNG KAO | Gut | 36 | 30 | |
2009 | Peginterferon alfa-2b or alfa-2a with ribavirin for hepatitis C | Hsu C.-S.; JIA-HORNG KAO | New England Journal of Medicine | 4 | 2 | |
2016 | Peginterferon Lambda-1a/ribavirin with daclatasvir or peginterferon alfa-2a/ribavirin with telaprevir for chronic hepatitis c genotype 1b | Flisiak R.; Kawazoe S.; Znoyko O.; Assy N.; Gadano A.; JIA-HORNG KAO ; Lee K.-S.; Zwirtes R.; Portsmouth S.; Dong Y.; Xu D.; Kumada H.; Srinivasan S. | Journal of Interferon and Cytokine Research | 10 | 9 | |
2015 | Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naive Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study | CHEN-HUA LIU ; WANG-HUEI SHENG ; HSIN-YUN SUN ; SZU-MIN HSIEH ; Lo Y.-C; CHUN-JEN LIU ; TUNG-HUNG SU ; HUNG-CHIH YANG ; Liu W.-C; PEI-JER CHEN ; DING-SHINN CHEN ; CHIEN-CHING HUNG ; JIA-HORNG KAO | Scientific Reports | 13 | 12 | |
2015 | Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial | CHEN-HUA LIU ; Huang, Chung-Feng; CHUN-JEN LIU ; Dai, Chia-Yen; Huang, Jee-Fu; JOU-WEI LIN ; Liang, Cheng-Chao; Yang, Sheng-Shun; Lin, Chih-Lin; TUNG-HUNG SU ; HUNG-CHIH YANG ; PEI-JER CHEN ; DING-SHINN CHEN ; Chuang, Wan-Long; JIA-HORNG KAO ; Yu, Ming-Lung | Scientific reports | 7 | 7 | |
2014 | Peginterferon α in the treatment of chronic hepatitis B | TAI-CHUNG TSENG ; JIA-HORNG KAO ; DING-SHINN CHEN | Expert Opinion on Biological Therapy | 19 | 17 | |
2016 | Pegylated IFN-α suppresses hepatitis C virus by promoting the DAPK-mTOR pathway | Liu W.-L.; HUNG-CHIH YANG ; Hsu C.-S; Wang C.-C; Wang T.-S; JIA-HORNG KAO ; DING-SHINN CHEN | Proceedings of the National Academy of Sciences of the United States of America | 9 | 9 | |
2010 | Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C | CHEN-HUA LIU ; Liang C.-C.; CHUN-JEN LIU ; JOU-WEI LIN ; Chen S.-I.; Hung P.-H.; Tsai H.-B.; Lai M.-Y.; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Clinical Infectious Diseases | 30 | 26 | |
2009 | Pegylated interferon α-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy | CHEN-HUA LIU ; Liang C.-C.; CHUN-JEN LIU ; Tsai H.-B.; Hung P.-H.; SHIH-JER HSU ; Chen S.-L.; JOU-WEI LIN ; Lai M.-Y.; Chen J.-H.; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Gut | 26 | 23 | |
2008 | Pegylated interferon α-2a versus standard interferon α-2a for treatment-naïve dialysis patients with chronic hepatitis C: A randomised study | CHEN-HUA LIU ; Liang C.-C.; JOU-WEI LIN ; Chen S.-I.; Tsai H.-B.; Chang C.-S.; Hung P.-H.; JIA-HORNG KAO ; CHUN-JEN LIU ; Lai M.-Y.; Chen J.-H.; PEI-JER CHEN ; DING-SHINN CHEN | Gut | 67 | 61 | |
2008 | Pegylated interferon-α-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial | CHEN-HUA LIU ; CHUN-JEN LIU ; Lin C.-L.; Liang C.-C.; SHIH-JER HSU ; Yang S.-S.; Hsu C.-S.; TAI-CHUNG TSENG ; Wang C.-C.; Lai M.-Y.; Chen J.-H.; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Clinical Infectious Diseases | 183 | 170 | |